Biodiversity to Develop Post-transplant Dx on BD Max System | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BD Diagnostics said today that Italian biotech and molecular diagnostics company Biodiversity will develop and commercialize tests tailored for BD's platform for the detection of infections in transplant patients, as part of a regional collaboration.

Biodiversity will develop a portfolio of molecular assays to run on the BD Max System's open architecture. The assays will be for patients who have undergone transplants.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.